Light Exposure

Mitochondrial ATP. Cytochrome C oxidase absorption. Photobiomodulation isn't a wellness trend — it's one of the most-studied therapeutic modalities of the past two decades, with hundreds of peer-reviewed papers and FDA 510(k) clearances for specific indications including hair growth (androgenetic alopecia) [evidence: [A] Strong — Afifi 2017 meta-analysis of 11 RCTs, 680 patients + 2019 update at 15 RCTs, 795 patients], mild-to-moderate acne [evidence: [B] Moderate — blue light at 415–450 nm has its own evidence base for Propionibacterium acnes destruction], and temporary muscle and joint pain relief [evidence: [B] Moderate — multiple RCTs and meta-analyses for knee osteoarthritis, chronic low back pain, tendinopathies].

Three Renew panels on the shelf today, sized for daily single-region work, whole-body sessions, and position-flexible protocols. All three publish spectrometer-measured irradiance at multiple distances. All three are honest about the wavelengths the literature actually supports — 660nm and 810/850nm carry the evidence; other wavelengths are present but aren't doing the heavy lifting.

A note on dose. The therapeutic window for photobiomodulation is approximately 2–30 J/cm² per body area per session per the most recent (2024) evidence synthesis [Frontiers in Medicine review PMC11358123]. Earlier Hamblin reviews cite a wider 4–60 J/cm² range; the field has narrowed. Below 2 J/cm², no effect. Past 30 J/cm², returns plateau. At 50–100 J/cm² per session, inhibitory effects emerge. This is the biphasic dose-response (Arndt-Schulz curve), and it's the most-violated principle in consumer red light marketing.

Premium-tier light therapy partnerships in progress for post-conference June onward.